Long-term beta-blocker therapy after acute myocardial infarction

Discontinuation of ß-blocker therapy in stabilized patients after acute myocardial infarction: A multicenter randomized noninferiority trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005903

Enrollment

2500

Registered

2021-02-18

Start date

2021-04-27

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients who have been diagnosed with acute myocardial infarction and have taken beta blockers for more than a year are randomly assigned to the beta blocker maintenance or suspension group. I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Male or female, 19 years of age or older - Diagnosed with acute myocardial infarction regardless of the time of myocardial infarction and has been treated for beta-blockers for more than a year - Signed Informed Consent Form

Exclusion criteria

Exclusion criteria: - less than 40% left ventricular blood pressure or has never had a cardiac ultrasonography in cardiac ultrasonography since an acute myocardial infarction. - Medication Therapy of heart failure -contraindications to beta blockers i)prior history of symptomatic asthma or chronic obstructive pulmonary disease ii)Patients with a history of 2-degree, 3-degree, or artificial pacemaker iii)If the investigator decision to used not beta-blockers -If the life anticipation 1year under, or Poor protocol compliance -History of atrial fibrillation -pregnant and breast-feeding

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular events [MACE], a composite of all-cause death, myocardial infarction [MI], hospitalization for heart failure	—

Secondary

Measure	Time frame
2 Years of all-cause Death After Random Allocation;2 Years of Cardiac death After Random Allocation;2 Years of myocardial infarction After Random Allocation;2 Years of All-cause hospitalizations After Random Allocation;2 Years of heart failure hospitalizations After Random Allocation;2 Years of Acute coronary syndrome hospitalizations After Random Allocation;2 Years of death or myocardial infarction After Random Allocation;2 Years of Cardiac death or myocardial infarction After Random Allocation;2 Years of myocardial infarction or heart failure hospitalizations After Random Allocation;2 Years of all re-CAG After Random Allocation;2 Years of myocardial infarction or all re-CAG After Random Allocation;2 Years of Cardiac death, myocardial infarction or all re-CAG After Random Allocation;2 Years of left ventricular implementation rate After Random Allocation;NT-proBNP at 2years;total medical expenses;quality of life scale;side effects of beta blocker	—

Measure

Time frame

2 Years of all-cause Death After Random Allocation;2 Years of Cardiac death After Random Allocation;2 Years of myocardial infarction After Random Allocation;2 Years of All-cause hospitalizations After Random Allocation;2 Years of heart failure hospitalizations After Random Allocation;2 Years of Acute coronary syndrome hospitalizations After Random Allocation;2 Years of death or myocardial infarction After Random Allocation;2 Years of Cardiac death or myocardial infarction After Random Allocation;2 Years of myocardial infarction or heart failure hospitalizations After Random Allocation;2 Years of all re-CAG After Random Allocation;2 Years of myocardial infarction or all re-CAG After Random Allocation;2 Years of Cardiac death, myocardial infarction or all re-CAG After Random Allocation;2 Years of left ventricular implementation rate After Random Allocation;NT-proBNP at 2years;total medical expenses;quality of life scale;side effects of beta blocker

—

Countries

Korea, Republic of

Contacts

Public ContactKyung Ui Hwang

Samsung Medical Center

ku.hwang@samsung.com+82-2-3410-3419

Outcome results